Skip to content

The RISAP-study: a Complex Intervention in Risk Communication and Shared Decision-making in General Practice

The RISAP-study: a Complex Intervention in Risk Communication and Shared Decision-making in General Practice

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01187056
Acronym
RISAP
Enrollment
179
Registered
2010-08-23
Start date
2007-11-30
Completion date
2012-07-31
Last updated
2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, High Cholesterol

Keywords

Shared decision-making, Risk information, Decision aids

Brief summary

General practitioners (GPs) and patients find it difficult to talk about risk of future disease, especially when patients have asymptomatic conditions, and treatment options are unlikely to cause immediate perceptible improvements in well-being. Further studies in risk communication for disease prevention are needed, as are studies about risk communication training for GPs. Aim: 1) to systematically develop, describe and evaluate a complex intervention comprising a training programme for GPs in risk communication and shared decision-making, 2) to evaluate the effect of the training programme on real-life consultations between GPs and patients with high cholesterol levels, and 3) to evaluate patients' reactions during and after the consultations. Hypothesis: 1) patients have better adherence to chosen treatment. The effect of the complex intervention, based around a training programme, will be evaluated in a cluster-randomised controlled trial with an intervention group and an active control group with 40 GPs and 280 patients in each group. The GPs receive a questionnaire at baseline and after 6 months about their attitudes towards risk communication and cholesterol-reducing medication. After each consultation with a participating high cholesterol-patient, the GPs will complete a questionnaire about decision satisfaction. The patients will receive a questionnaire at baseline and after 3 and 6 months. It includes questions about adherence to chosen treatment, self-rated health, patient enablement, and risk communication and decision-making effectiveness. Prescriptions, contacts to the health services, and cholesterol level will be drawn from the register of the National Health Service of Denmark at baseline and at 6 months. In both intervention group and active control group, 12 consultations will be observed and tape-recorded. The consultations will be divided between 4 GPs with each 3 patients. The patients from these 24 consultations will be interviewed immediately after the consultation and re-interviewed after 6 months.Eight purposefully selected GPs from the intervention group will be interviewed in a focus group 6 months after participation in the training programme. The process and context of the RISAP-study will be investigated in detail using an action research approach, in order to describe and analyse research choices, adaptation of intervention model to the specific context, and GPs' and patients' reactions to trial participation.

Interventions

2 x 2 hours of training (workshops)

Sponsors

TrygFonden, Denmark
CollaboratorINDUSTRY
University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- GPs in Region Central and Region North, Denmark, are invited to the study. Patients are at least 18 years old, and have high cholesterol corresponding to a recommendation for cholesterol-reducing medication according to Danish clinical guideline for general practice. The patients are recruited after their high cholesterol has been detected and when treatment options are to be discussed.

Exclusion criteria

\- Patients with CVD or DM are excluded from the study, as are patients already receiving cholesterol-reducing medication and patients unable to speak and read Danish.

Design outcomes

Primary

MeasureTime frame
The primary patient outcome is adherence to treatment choice.2010-08-01 - 2011-04-01

Secondary

MeasureTime frame
self-rated health2010-08-01 - 2011-04-01
anxiety2010-08-01 - 2011-04-01
enablement2010-08-01 - 2011-04-01
satisfaction with decision.2010-08-01 - 2011-04-01
satisfaction and confidence in decision2010-08-01 - 2011-04-01
number of contacts to health services2010-08-01 - 2011-04-01
satisfaction with communication,2010-08-01 - 2011-04-01

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026